American Journal of Gastroenterology, ISSN 0002-9270, 05/2018, Volume 113, Issue 5, pp. 779 - 780
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 06/2017, Volume 2017, Issue 6, pp. CD012143 - CD012143
Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs) are...
Hepacivirus - drug effects | Nucleic Acid Synthesis Inhibitors - therapeutic use | Nucleic Acid Synthesis Inhibitors - adverse effects | Antiviral Agents - therapeutic use | Humans | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - mortality | Simeprevir - therapeutic use | Cause of Death | Safety-Based Drug Withdrawals | Simeprevir - adverse effects | Randomized Controlled Trials as Topic | Placebos - therapeutic use | Antiviral Agents - adverse effects | Protease Inhibitors - adverse effects | Protease Inhibitors - therapeutic use | SUSTAINED VIROLOGICAL RESPONSE | PLUS PEGINTERFERON ALPHA-2B/RIBAVIRIN | PHASE-III TRIAL | NONNUCLEOSIDE POLYMERASE INHIBITOR | MEDICINE, GENERAL & INTERNAL | PEGYLATED INTERFERON ALPHA-2A | HCV GENOTYPE 1 | TREATMENT-EXPERIENCED PATIENTS | NS3/4A PROTEASE INHIBITOR | TREATMENT-NAIVE PATIENTS | PATIENT-REPORTED OUTCOMES | Index Medicus
Hepacivirus - drug effects | Nucleic Acid Synthesis Inhibitors - therapeutic use | Nucleic Acid Synthesis Inhibitors - adverse effects | Antiviral Agents - therapeutic use | Humans | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - mortality | Simeprevir - therapeutic use | Cause of Death | Safety-Based Drug Withdrawals | Simeprevir - adverse effects | Randomized Controlled Trials as Topic | Placebos - therapeutic use | Antiviral Agents - adverse effects | Protease Inhibitors - adverse effects | Protease Inhibitors - therapeutic use | SUSTAINED VIROLOGICAL RESPONSE | PLUS PEGINTERFERON ALPHA-2B/RIBAVIRIN | PHASE-III TRIAL | NONNUCLEOSIDE POLYMERASE INHIBITOR | MEDICINE, GENERAL & INTERNAL | PEGYLATED INTERFERON ALPHA-2A | HCV GENOTYPE 1 | TREATMENT-EXPERIENCED PATIENTS | NS3/4A PROTEASE INHIBITOR | TREATMENT-NAIVE PATIENTS | PATIENT-REPORTED OUTCOMES | Index Medicus
Journal Article
Surgical Endoscopy, ISSN 0930-2794, 2/2017, Volume 31, Issue 2, pp. 611 - 611
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00464-016-5305-z
Medicine & Public Health | Surgery | Gynecology | Hepatology | Gastroenterology | Abdominal Surgery | Proctology | Prevention | Emergency medicine | Pancreatitis | Diclofenac
Medicine & Public Health | Surgery | Gynecology | Hepatology | Gastroenterology | Abdominal Surgery | Proctology | Prevention | Emergency medicine | Pancreatitis | Diclofenac
Journal Article
Surgical Endoscopy, ISSN 0930-2794, 2/2017, Volume 31, Issue 2, pp. 602 - 610
We aimed to compare the efficacy of prophylactic, parenterally administered ceftazidime and rectally applied diclofenac sodium for the prophylaxis of...
Nonsteroidal | Medicine & Public Health | Surgery | Gynecology | Hepatology | Gastroenterology | Pancreatitis | Abdominal Surgery | ERCP | Anti-inflammatory agents | Proctology | SURGERY | RISK-FACTORS | METAANALYSIS | RECTAL INDOMETHACIN | POST-ERCP PANCREATITIS | PROPHYLACTIC ANTIBIOTICS | NSAIDS | SPHINCTEROTOMY | COMPLICATIONS | Abdominal Pain - prevention & control | Postoperative Complications - etiology | Prospective Studies | Pancreatitis - etiology | Humans | Middle Aged | Postoperative Complications - prevention & control | Cholangiopancreatography, Endoscopic Retrograde - adverse effects | Administration, Rectal | Male | Pancreatitis - prevention & control | Incidence | Young Adult | Anti-Bacterial Agents - therapeutic use | Aged, 80 and over | Adult | Female | Diclofenac - therapeutic use | Abdominal Pain - etiology | Double-Blind Method | Pancreatitis - epidemiology | Postoperative Complications - epidemiology | Abdominal Pain - epidemiology | Administration, Intravenous | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Aged | Ceftazidime - therapeutic use | Prevention | Clinical trials | Endoscopic retrograde cholangiopancreatography | Amylases | Diclofenac
Nonsteroidal | Medicine & Public Health | Surgery | Gynecology | Hepatology | Gastroenterology | Pancreatitis | Abdominal Surgery | ERCP | Anti-inflammatory agents | Proctology | SURGERY | RISK-FACTORS | METAANALYSIS | RECTAL INDOMETHACIN | POST-ERCP PANCREATITIS | PROPHYLACTIC ANTIBIOTICS | NSAIDS | SPHINCTEROTOMY | COMPLICATIONS | Abdominal Pain - prevention & control | Postoperative Complications - etiology | Prospective Studies | Pancreatitis - etiology | Humans | Middle Aged | Postoperative Complications - prevention & control | Cholangiopancreatography, Endoscopic Retrograde - adverse effects | Administration, Rectal | Male | Pancreatitis - prevention & control | Incidence | Young Adult | Anti-Bacterial Agents - therapeutic use | Aged, 80 and over | Adult | Female | Diclofenac - therapeutic use | Abdominal Pain - etiology | Double-Blind Method | Pancreatitis - epidemiology | Postoperative Complications - epidemiology | Abdominal Pain - epidemiology | Administration, Intravenous | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Aged | Ceftazidime - therapeutic use | Prevention | Clinical trials | Endoscopic retrograde cholangiopancreatography | Amylases | Diclofenac
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2015, Volume 2015, Issue 3, p. CD010605
Background Acute pancreatitis is a common and potentially lethal disease with increasing incidence. Severe cases are characterised by high mortality, and...
Acute Disease | METAANALYSIS | Humans | BIAS | Pancreatitis | GUIDELINES | Male | Enteral Nutrition | NECROTIZING PANCREATITIS | RANDOMIZED CONTROLLED-TRIAL | BACTERIAL TRANSLOCATION | Randomized Controlled Trials as Topic | Probiotics | MEDICINE, GENERAL & INTERNAL | Immunotherapy | DOUBLE-BLIND | EMPIRICAL-EVIDENCE | Dietary Fiber | Female | PARENTERAL-NUTRITION | MODERATE ACUTE-PANCREATITIS | Dietary Supplements | Enteral Nutrition - methods | Enteral Nutrition - mortality | Immunotherapy - methods | Pancreatitis - therapy | Pancreatitis - mortality | Immunotherapy - mortality | Dietary Fiber - therapeutic use | Probiotics - therapeutic use
Acute Disease | METAANALYSIS | Humans | BIAS | Pancreatitis | GUIDELINES | Male | Enteral Nutrition | NECROTIZING PANCREATITIS | RANDOMIZED CONTROLLED-TRIAL | BACTERIAL TRANSLOCATION | Randomized Controlled Trials as Topic | Probiotics | MEDICINE, GENERAL & INTERNAL | Immunotherapy | DOUBLE-BLIND | EMPIRICAL-EVIDENCE | Dietary Fiber | Female | PARENTERAL-NUTRITION | MODERATE ACUTE-PANCREATITIS | Dietary Supplements | Enteral Nutrition - methods | Enteral Nutrition - mortality | Immunotherapy - methods | Pancreatitis - therapy | Pancreatitis - mortality | Immunotherapy - mortality | Dietary Fiber - therapeutic use | Probiotics - therapeutic use
Journal Article
Pancreatology, ISSN 1424-3903, 2017, Volume 17, Issue 3, pp. S87 - S87
Infectious complications including infected pancreatic necrosis, pneumonia, urinary tract infection (UTI), positive blood cultures, sepsis, and other...
Endocrinology & Metabolism | Gastroenterology and Hepatology | Pregnancy | Pneumonia | Antibiotics | Pancreatitis | Chronic infection | Gangrene | Sepsis | Urinary tract infections | Malignancy | Urinary tract | Pancreas | SAP protein
Endocrinology & Metabolism | Gastroenterology and Hepatology | Pregnancy | Pneumonia | Antibiotics | Pancreatitis | Chronic infection | Gangrene | Sepsis | Urinary tract infections | Malignancy | Urinary tract | Pancreas | SAP protein
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 09/2017, Volume 2017, Issue 9
Background Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals...
SUSTAINED VIROLOGICAL RESPONSE | MEDICINE, GENERAL & INTERNAL | PEGYLATED INTERFERON ALPHA-2A | SURROGATE END-POINTS | NS5B POLYMERASE INHIBITOR | HCV GENOTYPE 1 | PLUS PEGINTERFERON ALPHA-2A | NS3/4A PROTEASE INHIBITOR | TREATMENT-NAIVE PATIENTS | PREVIOUSLY UNTREATED PATIENTS | PATIENT-REPORTED OUTCOMES
SUSTAINED VIROLOGICAL RESPONSE | MEDICINE, GENERAL & INTERNAL | PEGYLATED INTERFERON ALPHA-2A | SURROGATE END-POINTS | NS5B POLYMERASE INHIBITOR | HCV GENOTYPE 1 | PLUS PEGINTERFERON ALPHA-2A | NS3/4A PROTEASE INHIBITOR | TREATMENT-NAIVE PATIENTS | PREVIOUSLY UNTREATED PATIENTS | PATIENT-REPORTED OUTCOMES
Journal Article